4. The role of the epidermal growth factor receptor and the c‐erbB‐2 protein in breast cancer

Breast cancer cells are derived from epithelial cells lining the ducts of the breast. One of the fundamental characteristics that distinguish tumour cells from normal cells is that cancer cells grow in an apparently unregulated way. Understanding the mechanisms that regulate the growth and differentiation of normal breast epithelial cells and the differences between these systems in cancer cells is one of the central goals of research into the cell biology of breast cancer.

[1]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[2]  J. Winstanley,et al.  The long term prognostic significance of c-erbB-2 in primary breast cancer. , 1991, British Journal of Cancer.

[3]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[4]  J. Bártková,et al.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.

[5]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[6]  J. Bacus,et al.  HER-2/neu oncogene expression and proliferation in breast cancers. , 1990, The American journal of pathology.

[7]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[8]  R. Gelber,et al.  c-erbB-2 protein expression in node negative breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Shilo,et al.  Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain. , 1990, European journal of biochemistry.

[10]  M. Sternberg,et al.  A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. , 1990, Protein engineering.

[11]  N. Lemoine,et al.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. , 1990, Oncogene.

[12]  K. Leslie,et al.  Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. , 1990, Archives of pathology & laboratory medicine.

[13]  T. Yagi,et al.  Induction of a variety of tumors by c‐erbB2 and clonal nature of lymphomas even with the mutated gene (Val659‐‐‐‐Glu659). , 1990, The EMBO journal.

[14]  A. Howell,et al.  C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. , 1990, British Journal of Cancer.

[15]  G. Hortobagyi,et al.  c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.

[16]  M. Aapro,et al.  Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. , 1989, Cancer research.

[17]  H. Lehväslaiho,et al.  Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase , 1989, The Journal of cell biology.

[18]  C. Theillet,et al.  Proto-oncogene amplification and human breast tumor phenotype. , 1989, Oncogene.

[19]  P. Quirke,et al.  c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. , 1989, British Journal of Cancer.

[20]  M. Waterfield,et al.  Identification of a novel autophosphorylation site (P4) on the epidermal growth factor receptor. , 1989, The Biochemical journal.

[21]  J. Varley,et al.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.

[22]  S. Steinberg,et al.  Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. , 1989, Cancer research.

[23]  W. Gullick,et al.  Neu receptor dimerization , 1989, Nature.

[24]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[25]  M. Fernö,et al.  HER2/neu AMPLIFICATION AND COMEDO TYPE BREAST CARCINOMA , 1989, The Lancet.

[26]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[27]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[28]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[29]  R. Weinberg,et al.  Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[31]  M. Greene,et al.  The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.

[32]  A. Howell,et al.  Epidermal and transforming growth factor alpha in patients with breast tumours. , 1989, British Journal of Cancer.

[33]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[34]  D. Horsfall,et al.  The significance of oncogene amplification in primary breast cancer , 1989, International journal of cancer.

[35]  M. Mathieu,et al.  Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance , 1989, International journal of cancer.

[36]  M. Kraus,et al.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.

[37]  H. Lehväslaiho,et al.  A chimeric EGF‐R‐neu proto‐oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. , 1989, The EMBO journal.

[38]  A. Ullrich,et al.  HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. , 1989, The EMBO journal.

[39]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[40]  B. Gusterson,et al.  c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.

[41]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[42]  R. Lidereau,et al.  Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. , 1988, Oncogene research.

[43]  R. Derynck,et al.  Transforming growth factor α , 1988, Cell.

[44]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[45]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[46]  S. Bates,et al.  Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. , 1988, Molecular endocrinology.

[47]  G. M. Walton,et al.  Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies , 1988, Cell.

[48]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[49]  P Chambon,et al.  Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[51]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[53]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[54]  J. Yokota,et al.  Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. B. Santon,et al.  Epidermal growth factor and its receptor , 1987, Molecular and Cellular Endocrinology.

[56]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.

[57]  D. Goeddel,et al.  Synthesis of Messenger RNAs for Transforming Growth Factors α and β and the Epidermal Growth Factor Receptor by Human Tumors , 1987 .

[58]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[59]  E. Rozengurt.  Early signals in the mitogenic response. , 1986, Science.

[60]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[61]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[62]  R. Cummings,et al.  The oligosaccharide moieties of the epidermal growth factor receptor in A-431 cells. Presence of complex-type N-linked chains that contain terminal N-acetylgalactosamine residues. , 1985, The Journal of biological chemistry.

[63]  G. Carpenter.  Epidermal Growth Factor: Biology and Receptor Metabolism , 1985, Journal of Cell Science.

[64]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[65]  J. Downward,et al.  Autophosphorylation sites on the epidermal growth factor receptor , 1984, Nature.

[66]  D. Garbers,et al.  The kinetics of tyrosine phosphorylation by the purified epidermal growth factor receptor kinase of A-431 cells. , 1983, The Journal of biological chemistry.

[67]  A. Ullrich,et al.  Identification of autophosphorylation sites of HER2/neu. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[68]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  W. Gullick.  Growth factors and oncogenes in breast cancer. , 1990, Progress in growth factor research.

[70]  T. Fleming,et al.  Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. , 1989, Oncogene.

[71]  R. Zeillinger,et al.  HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. , 1989, Oncogene.

[72]  M. Cline,et al.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. , 1989, Oncogene.

[73]  W. Gullick.  Chapter 16 A comparison of the structures of single polypeptide chain growth factor receptors that possess protein tyrosine kinase activity , 1988 .

[74]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.